Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : J&J to work with India on compensation for recalled hip implants

share with twitter share with LinkedIn share with facebook
share via e-mail
09/07/2018 | 06:30am EDT
Security guards stand outside the office of Johnson & Johnson in Mumbai

MUMBAI (Reuters) - Johnson & Johnson (J&J) said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

This follows last week's recommendation from a government panel that J&J pay at least 2 million rupees ($27,812) to each patient for the faulty ASR hip implant. The federal government has asked states to help patients get relief soon.

About 93,000 people worldwide received ASR implants which were recalled in 2010. The Indian panel said in its report that about 4,700 of those people were in India.

Given the recent committee report, "we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need", a J&J spokeswoman said in a statement to Reuters, adding the firm was committed to support all ASR patients in India.

Sushobhan Dasgupta, a senior J&J executive in India, has, however, told Indian newspaper Mint that the company "will not pay people who had an ASR implant if they are doing well".

The company is not okay with the methodology used by the Indian panel, Dasgupta told the paper in an interview https://www.livemint.com/Companies/d5JxJ6YLFqLsUu8sRtf2fO/Not-all-hip-implants-faulty-everyone-wont-be-compensated.html published on Friday. The report has "factual inaccuracies" and "the conclusions could also be inaccurate", he added.

In 2013, J&J agreed to pay http://reut.rs/I20AZB nearly $2.5 billion to settle thousands of lawsuits from patients in the United States who said they were injured by the implants.

In India, the company paid $2 million to patients for repeat surgeries and about $250,000 in related diagnostic costs under its ASR reimbursement programme, but the government panel has criticised J&J for offering no compensation.

Metal hip implant systems such as ASR were designed to be more durable than a traditional metal-on-plastic, ball-and-socket design. But many Indian patients suffered adverse reactions to the implant, the panel said.

J&J entered the Indian market in 1947 when it started selling its now-ubiquitous baby powder. It has in recent years faced issues such as price caps on medical devices.

(Reporting by Aditya Kalra, Writing by Krishna N. Das; Editing by Darren Schuettler and Himani Sarkar)

By Aditya Kalra

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
07:01aJOHNSON & JOHNSON : puts up big profit numbers for 2Q
06:58aMARKET SNAPSHOT: U.S. Stocks Set To Tread Water As Investors Await Trio Of Ba..
06:53aJOHNSON & JOHNSON : quarterly profit jumps 41.8%
06:49aJOHNSON & JOHNSON : 2Q Earnings Snapshot
06:41aJOHNSON & JOHNSON : Reports 2019 Second-Quarter Results
02:48aJudge to Weigh Closely Watched Opioid Case -- WSJ
07/15JOHNSON & JOHNSON : Judge to Weigh $17 Billion Opioid Case Against Johnson & Joh..
07/15JOHNSON & JOHNSON : Opioid 'kingpin' J&J fueled epidemic, Oklahoma argues at tri..
07/15JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2019
07/15LATEST : Oklahoma prosecutor calls drugmaker opioid 'kingpin'
More news
Financials (USD)
Sales 2019 81 267 M
EBIT 2019 25 533 M
Net income 2019 18 770 M
Debt 2019 7 363 M
Yield 2019 2,79%
P/E ratio 2019 19,6x
P/E ratio 2020 17,7x
EV / Sales2019 4,49x
EV / Sales2020 4,13x
Capitalization 358 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 149  $
Last Close Price 135  $
Spread / Highest target 22,5%
Spread / Average Target 10,5%
Spread / Lowest Target -7,21%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON4.07%372 000
PFIZER-2.06%238 617
ROCHE HOLDING LTD.7.93%233 930
ROCHE HOLDING9.69%233 930
NOVARTIS17.29%206 941